Fulgent Genetics, Inc. (FLGT)
| Market Cap | 1.61B |
| Revenue (ttm) | 135.12M |
| Net Income (ttm) | 47.71M |
| Shares Out | 22.06M |
| EPS (ttm) | 2.14 |
| PE Ratio | 32.36 |
| Forward PE | 13.64 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $69.24 |
| Previous Close | $66.23 |
| Change ($) | 3.01 |
| Change (%) | 4.54% |
| Day's Open | 66.42 |
| Day's Range | 65.99 - 69.47 |
| Day's Volume | 1,118,374 |
| 52-Week Range | 6.75 - 76.74 |
Typically speaking, contrarian involves going against the grain, either by buying stocks most other investors are selling, or vice versa. Yet, this exact sentiment towards contrarian investin...
FULGENT GENETIC (FLGT) closed at $69.07 in the latest trading session, marking a -1.1% move from the prior day.
Both of these businesses prospered even during a volatile year -- and the coming months could be even more impressive.
These winners are positioned for gains even after COVID.
A Wall Street analyst downgraded the genetics testing provider.
As of late, it has definitely been a great time to be an investor in Fulgent Genetics (FLGT).
TEMPLE CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutio...
Fulgent's core genetic testing business is recovering and should improve even further due to synergies with the COVID-19 business. Many people thought COVID-19 would dissipate in 2021 as the v...
Both of these stocks are up more than 300% in 2020 and have room to run.
Helping the world cope with a pandemic increased sales by several multiples for these companies.
Investors in fast-moving biotechs made out like bandits.
Following a competitive process, Fulgent was selected to extend its support of the NYC DOE public school testing managed by the NYC Test and Trace Corps with on-site staffing and RT-PCR tests ...
Could this genetic testing provider turn its coronavirus bump into long-term share price growth?
We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
Companies with fast growth and predictable trends are better bets in a frothy market.
Check out these five high earnings yield stocks that can make you rich, irrespective of the Santa rally or a year-end pullback.
Should you invest in shares of this high-flying coronavirus stock before it's too late?
The encore to a great 2019: Even more gains this year.
Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.
Top Ranked Momentum Stocks to Buy for December 10th
Although vaccine makers are dominating headlines, these diagnostic companies will remain relevant in the fight against COVID-19.
The COVID-19 pandemic continues to provide a tailwind for the genetic testing specialist.
There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.
Investors have been selling these stocks, but patient investors should take advantage of the opportunity.
Wall Street seems worried that the arrival of coronavirus vaccines will take the wind out of the sails of this genetic and medical testing company. That view misses the big picture.
Here are seven of the best cheap stocks for December that I'd consider buying The post 7 of the Best Cheap Stocks for December appeared first on InvestorPlace. More From InvestorPlace Why Ever...
TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutio...
TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutio...
Top Ranked Momentum Stocks to Buy for November 17th
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and...
Two new breakout stocks for Week 47 with better than 10% short-term upside potential. This past week one out of four stocks gained over 10%+ with YCBD +19.5% at the peak and the portfolio clos...
The Virus Testing Stocks Pullback Opportunity (NASDAQ: CODX) (NASDAQ: FLGT) (OTC: ALST) (NYSE: LH)
TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutio...
Coronavirus testing demand caused revenue and profit to surge last quarter.
Fulgent Genetics, Inc.'s (FLGT) CEO Ming Hsieh on Q3 2020 Results - Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q3 2020 Results - Quick Version Earnings Call Transcript
Fulgent has a successful genetic testing business growing at 50% that should benefit from the reduced cost of sequencing. However, more recently, Fulgent's COVID-19 business has seen greater s...
TEMPLE CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 f...
Growth-focused investors may want to consider investing in the following small-cap stocks, as they represent companies whose trailing 12-month pro forma earnings per share (EPS) improved drama...
Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 empl...
Fulgent Genetics partners with NYC public schools on Covid-19 testing
With students returning to school, the largest public school district in the U.S.
Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform
Fulgent Genetics (FLGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
TEMPLE CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solu...
New York City will use the company's COVID-19 test in its public school system.
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
COVID-19 and Influenza A/B will be run on single nasal swab at no additional cost to patients COVID-19 and Influenza A/B will be run on single nasal swab at no additional cost to patients
Test and Trace (T2) Program will use Picture by Fulgent at-home test for hundreds of thousands of students to help ensure a safe return to school Test and Trace (T2) Program will use Picture b...
Small caps lag the broader market, so is there opportunity?
Nancy Prial, Essex Investment Management portfolio manager, on whether there's opportunity among small cap stocks. With CNBC's Dominic Chu and the Fast Money traders, Guy Adami, Karen Finerman...
The Nasdaq Composite failed to hit a record for the first time in a week.
About FLGT
Fulgent Genetics, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics h... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 29, 2016 |
| CEO Ming Hsieh | Employees 473 |
| Stock Exchange NASDAQ | Ticker Symbol FLGT |
Financial Performance
In 2019, FLGT's revenue was $32.53 million, an increase of 52.35% compared to the previous year's $21.35 million. Losses were -$411,000, -92.67% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price forecast is 62.50, which is a decrease of -9.73% from the latest price.